Combined sales for the company's blockbuster GLP-1 drugs Zepbound and Mounjaro exceeded $1 billion, with each showing triple-digit growth.
Get this delivered to your inbox, and more info about our products and services.
The drugmaker posted a strong third quarter, driven by sales of its popular GLP-1 medications
The results come as Eli Lilly works to maintain its edge over Novo Nordisk in the booming market for a class of obesity and…
Eli Lilly's fourth-quarter earnings come as it tries to maintain its advantage over Novo Nordisk in the GLP-1 market.
Lilly hiked its full-year sales outlook by $2 billion, and also raised its adjusted profit guidance.
Bank of America's new price target has shares of Eli Lilly climbing 22% from here.
Eli Lilly hiked its 2025 guidance and posted second-quarter earnings that topped estimates on strong demand for its blockbuster…
